Sort
48,018 grants matching “immunotherapy”
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer
$379,660Rebekah White · University Of California, San Diego · R01 · FY2023 · CA
CEA TARGETED IMMUNOTHERAPEUTICS
$379,655Andrew A. Raubitschek · Beckman Research Institute/City Of Hope · P01 · FY2011 · CA
UNIVERSITY OF COLORADO SOUTHWEST ONCOLOGY GROUP
$379,635University Of Colorado Denver · U10 · FY2001 · CA
Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastoma
$379,634Rakesh K. Jain · Massachusetts General Hospital · R01 · FY2022 · CA
Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastoma
$379,634Rakesh K. Jain · Massachusetts General Hospital · R01 · FY2025 · CA
Origins and functions of pancreatic cancer-associated fibroblasts
$379,585Mara H. Sherman · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Ricin-Mechanism, Transition State and Inhibitor Design
$379,534Vern L. Schramm · Albert Einstein College Of Medicine · R01 · FY2010 · CA
Imaging T-cell Activation and Co-stimulation in Prostate Cancer Immunotherapy
$379,518Vladimir Ponomarev · Sloan-Kettering Inst Can Research · R01 · FY2015 · CA
EBV Specific T-cells from 3rd party donors for treatment of EBV-associated malign
$379,518Richard J O'Reilly · Sloan-Kettering Inst Can Research · R21 · FY2012 · CA
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients with High-
$379,518Nai-Kong V Cheung · Sloan-Kettering Inst Can Research · R21 · FY2012 · CA
Imaging T-cell Activation and Co-stimulation in Prostate Cancer Immunotherapy
$379,518Vladimir Ponomarev · Sloan-Kettering Inst Can Research · R01 · FY2012 · CA
Macrophage-targeted lncRNA-regulating nanoparticles for glioblastoma treatment
$379,513Edjah Nduom · Emory University · R01 · FY2024 · NS
DNA damaging therapy and immune response in small cell lung cancer subtypes
$379,504Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
TRAINING IN THE IMMUNOBIOLOGY AND MOLECULAR CELL BIOLOGY OF CANCER
$379,475Robert David Schreiber · Washington University · T32 · FY2023 · CA
Tumor Growth and Microenvironment Influence T Cell Tolerance to Tumor Antigens
$379,457Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Control of Effector and Memory T Cell Development by Inflammatory Signals
$379,454Susan M Kaech · Yale University · R01 · FY2012 · AI
ST8Sia6 expression on tumors inhibits the immune response
$379,434Virginia Smith Shapiro · Mayo Clinic Rochester · R01 · FY2024 · CA
Mismatch Repair and Carcinogenesis
$379,433Richard Fishel · Ohio State University · R01 · FY2022 · CA
Breaking Tolerance to Induce Tumor-Specific Cytotoxic CD4 Th1 Cells
$379,427Adam J Adler · University Of Connecticut Sch Of Med/Dnt · R01 · FY2014 · AI
Tumor Growth and Microenvironment Influence T Cell Tolerance to Tumor Antigens
$379,424Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Leveraging the TCR Repertoire to identify target neoantigens in FLT3-ITD positive Acute Myeloid Leukemia
$379,419Houda Alachkar · University Of Southern California · R01 · FY2021 · CA
Validating Urine Derived Cancer Cells (UDCC) -- Non-Invasive and Living Liquid Biopsies -- in Bladder Cancer Clinics
$379,392Xuefeng Liu · Ohio State University · R33 · FY2022 · CA
T cell homing to the kidney contributes to salt retention and blood pressure regulation
$379,375Shengyu Mu · Univ Of Arkansas For Med Scis · R01 · FY2020 · HL
Delineating how nucleic acid sensing in tumor cells regulate anti-tumor immune responses
$379,354Sunny Shin · University Of Pennsylvania · P01 · FY2023 · CA
PROTECTION DURING GRAM NEGATIVE BACTERIAL SEPSIS
$379,344University Of Minnesota Twin Cities · R01 · FY2001 · GM